Status: Recruiting
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Participants needed: 36
Trial details
Phase: Phase 2Age: 40-80Biological sex: AllType: InterventionalSponsor: Hillhurst Biopharmaceuticals, Inc.Updated: Aug 10, 2026Locations: 5
Eligibility criteria
Signed informed consent. [+21]
Atypical parkinsonism, including parkinsonism due to drugs, metabolic disorders,... [+57]